Washington Trust Advisors, Inc. Ascendis Pharma A/S Transaction History
Washington Trust Advisors, Inc.
- $1.19 Billion
- Q2 2025
A detailed history of Washington Trust Advisors, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 52 shares of ASND stock, worth $10,770. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52
Previous 52
-0.0%
Holding current value
$10,770
Previous $8,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ASND
# of Institutions
279Shares Held
59.9MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.13 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.13 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.03 Billion15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$917 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$882 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.6B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...